Entrada Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TRDA Nasdaq 2836 www.entradatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Entrada Therapeutics, Inc.

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - Jun 3rd, 2025 5:00 am
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 2nd, 2025 2:30 pm
Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU - May 29th, 2025 9:10 am
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - May 28th, 2025 5:00 am
Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results - May 11th, 2025 6:51 am
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates - May 8th, 2025 6:15 am
Entrada Therapeutics Reports First Quarter 2025 Financial Results - May 8th, 2025 5:00 am
Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release - May 1st, 2025 8:01 am
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for - Apr 29th, 2025 8:01 am
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? - Apr 10th, 2025 7:30 am
Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment - Mar 25th, 2025 8:03 am
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - Mar 24th, 2025 5:00 am
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next - Mar 2nd, 2025 5:46 am
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates - Feb 27th, 2025 6:25 am
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - Feb 27th, 2025 5:00 am
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA - Feb 26th, 2025 7:19 am
FDA removes clinical hold on Entrada’s Duchenne therapy - Feb 25th, 2025 11:05 am
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday - Feb 24th, 2025 7:14 am
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 - Feb 24th, 2025 5:00 am
Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now - Feb 12th, 2025 5:58 am